Plain-English translation of NCT03043313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied how well works when combined with , or when given by itself, in people with advanced colorectal cancer that has spread to other parts of the body. The trial compared two approaches: some participants received both medications together, while others received alone to see which treatment worked better at slowing the cancer.
Advanced colorectal cancer is difficult to treat, and most standard treatments stop working over time. This trial was designed to test whether this medication combination could offer a new treatment option for people whose cancer has specific genetic characteristics and who have already tried other therapies.
Participants were enrolled into different groups. Some received both (taken by mouth twice daily) and (given through an IV infusion) in repeating 21-day cycles. Others received alone, with the option to add later if their cancer did not respond. Participants would have had regular clinic visits for treatment and monitoring to check how well the medication was working and to watch for any side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States